Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes

European Neuropsychopharmacology

Volumn 22, Issue 9, 2012, Pages 625-631

  Vehof, Jelle ^a   Burger, Huibert ^a   Wilffert, Bob ^b   Al Hadithy, Asmar ^b,c   Alizadeh, Behrooz Z ^a   Snieder, Harold ^a   Kahn, René S ^d   Linszen, Don H ^e   Os, Jim van ^f,g   Wiersma, Durk ^a   Bruggeman, Richard ^a   Cahn, Wiepke ^d   de Haan, Lieuwe ^e   Krabbendam, Lydia ^f   Myin Germeys, Inez ^f  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Dopamine; Pharmacogenetics; Polymorphism; Response; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CAUCASIAN; CLINICAL GLOBAL IMPRESSION SCALE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSIS; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D3;

EID: 84865001811     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.01.006     Document Type: Article

References (48)

1. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40(7):827-834.
2. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49(8):615-623.
3. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
4. Anttila S., Illi A., Kampman O., Mattila K.M., Lehtimaki T., Leinonen E. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004, 14(5):303-307.
5. Arranz M., Collier D., Sodhi M., Ball D., Roberts G., Price J., Sham P., Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995, 346(8970):281-282.
6. Arranz M.J., Collier D.A., Munro J., Sham P., Kirov G., Sodhi M., Roberts G., Price J., Kerwin R.W. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci. Lett. 1996, 217(2-3):177-178.
7. Arranz M.J., Munro J., Owen M.J., Spurlock G., Sham P.C., Zhao J., Kirov G., Collier D.A., Kerwin R.W. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry 1998, 3(1):61-66.
8. Arranz M.J., Munro J., Sham P., Kirov G., Murray R.M., Collier D.A., Kerwin R.W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 1998, 32(2):93-99.
9. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., Lesch K.P., Meyer J.F., Sham P., Collier D.A., Murray R.M., Kerwin R.W. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355(9215):1615-1616.
10. Arranz M.J., Munro J., Osborne S., Collier D., Kerwin R.W. Difficulties in replication of results. Lancet 2000, 356(9238):1359-1360.
11. Bakker R.C., Brandjes D.P. Hyperhomocysteinaemia and associated disease. Pharm. World Sci. 1997, 19(3):126-132.
12. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 2004, 161(10):1798-1805.
13. Derks E.M., Fleischhacker W.W., Boter H., Peuskens J., Kahn R.S. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?. J. Clin. Psychopharmacol. 2010, vol. 30(no. 2):176-180. EUFEST Study Group.
14. Freeman J.M., Finkelstein J.D., Mudd S.H. Folate-responsive homocystinuria and "schizophrenia". A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N. Engl. J. Med. 1975, 292(10):491-496.
15. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10(1):111-113.
16. Hazelwood L.A., Sanders-Bush E. His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol. Pharmacol. 2004, 66(5):1293-1300.
17. Hwang R., Shinkai T., De Luca V., Muller D.J., Ni X., Macciardi F., Potkin S., Lieberman J.A., Meltzer H.Y., Kennedy J.L. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology 2005, 181(1):179-187.
18. Jonsson E., Nothen M.M., Bunzel R., Propping P., Sedvall G. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996, 347(9018):1831.
19. Jonsson E.G., Nothen M.M., Grunhage F., Farde L., Nakashima Y., Propping P., Sedvall G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999, 4(3):290-296.
20. Joober R., Benkelfat C., Brisebois K., Toulouse A., Turecki G., Lal S., Bloom D., Labelle A., Lalonde P., Fortin D., Alda M., Palmour R., Rouleau G.A. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J. Psychiatry Neurosci. 1999, 24(2):141-146.
21. Joober R., Benkelfat C., Lal S., Bloom D., Labelle A., Lalonde P., Turecki G., Rozen R., Rouleau G.A. Association between the methylenetetrahydrofolate reductase 677C->T missense mutation and schizophrenia. Mol. Psychiatry 2000, 5(3):323-326.
22. Joober R., Toulouse A., Benkelfat C., Lal S., Bloom D., Labelle A., Lalonde P., Turecki G., Rouleau G.A. DRD3 and DAT1 genes in schizophrenia: an association study. J. Psychiatr. Res. 2000, 34(4-5):285-291.
23. Laakso A., Pohjalainen T., Bergman J., Kajander J., Haaparanta M., Solin O., Syvalahti E., Hietala J. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet. Genomics 2005, 15(6):387-391.
24. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63(10):892-909.
25. Lane H.Y., Hsu S.K., Liu Y.C., Chang Y.C., Huang C.H., Chang W.H. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J. Clin. Psychopharmacol. 2005, 25(1):6-11.
26. Lencz T., Robinson D.G., Xu K., Ekholm J., Sevy S., Gunduz-Bruce H., Woerner M.G., Kane J.M., Goldman D., Malhotra A.K. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am. J. Psychiatry 2006, 163(3):529-531.
27. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 1998, 44(11):1099-1117.
28. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 1996, 225(3):1068-1072.
29. Malhotra A.K., Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry 1996, 153(8):1092-1094.
30. Malhotra A.K., Goldman D., Buchanan R.W., Rooney W., Clifton A., Kosmidis M.H., Breier A., Pickar D. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol. Psychiatry 1998, 3(1):72-75.
31. Masellis M., Paterson A.D., Badri F., Lieberman J.A., Meltzer H.Y., Cavazzoni P., Kennedy J.L. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 1995, 346(8982):1108.
32. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., Cola P., Howard A., Badri F., Nothen M.M., Kalow W., Kennedy J.L. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19(2):123-132.
33. Oterino A., Toriello M., Valle N., Castillo J., Alonso-Arranz A., Bravo Y., Ruiz-Alegria C., Quintela E., Pascual J. The relationship between homocysteine and genes of folate-related enzymes in migraine patients. Headache 2010, 50(1):99-168.
34. Parsons M.J., D'Souza U.M., Arranz M.J., Kerwin R.W., Makoff A.J. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 2004, 56(6):406-410.
35. Pohjalainen T., Rinne J.O., Nagren K., Lehikoinen P., Anttila K., Syvalahti E.K., Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 1998, 3(3):256-260.
36. Regland B., Johansson B.V., Grenfeldt B., Hjelmgren L.T., Medhus M. Homocysteinemia is a common feature of schizophrenia. J. Neural Transm. Gen. Sect. 1995, 100(2):165-169.
37. Reynolds G.P., Yao Z., Zhang X., Sun J., Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur. Neuropsychopharmacol. 2005, 15(2):143-151.
38. Schafer M., Rujescu D., Giegling I., Guntermann A., Erfurth A., Bondy B., Moller H.J. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am. J. Psychiatry 2001, 158(5):802-804.
39. Scharfetter J., Chaudhry H.R., Hornik K., Fuchs K., Sieghart W., Kasper S., Aschauer H.N. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur. Neuropsychopharmacol. 1999, 10(1):17-20.
40. Schwartz J.C., Diaz J., Pilon C., Sokoloff P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev. 2000, 31(2-3):277-287.
41. Scott S.C., Goldberg M.S., Mayo N.E. Statistical assessment of ordinal outcomes in comparative studies. J. Clin. Epidemiol. 1997, 50(1):45-55.
42. Shaikh S., Collier D.A., Sham P.C., Ball D., Aitchison K., Vallada H., Smith I., Gill M., Kerwin R.W. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum. Genet. 1996, 97(6):714-719.
43. Shi J., Gershon E.S., Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 2008, 104(1-3):96-107.
44. Sodhi M.S., Arranz M.J., Curtis D., Ball D.M., Sham P., Roberts G.W., Price J., Collier D.A., Kerwin R.W. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995, 7(1):169-172.
45. Staddon S., Arranz M.J., Mancama D., Mata I., Kerwin R.W. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 2002, 162(1):18-23.
46. Szekeres G., Keri S., Juhasz A., Rimanoczy A., Szendi I., Czimmer C., Janka Z. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 124B(1):1-5.
47. Tsuang M.T., Lyons M.J., Faraone S.V. Heterogeneity of schizophrenia conceptual models and analytic strategies. Br. J. Psychiatry 1990, 156:17-26.
48. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., Jablenski A., Regier D., Sartorius N. SCAN. Schedules for clinical assessment in neuropsychiatry. Arch. Gen. Psychiatry 1990, 47(6):589-593.